|1.||Schally, Andrew V: 8 articles (06/2015 - 11/2010)|
|2.||Block, Norman L: 5 articles (06/2015 - 02/2012)|
|3.||Rick, Ferenc G: 5 articles (06/2015 - 09/2012)|
|4.||Zarandi, Marta: 5 articles (01/2014 - 11/2010)|
|5.||Vidaurre, Irving: 4 articles (01/2014 - 11/2010)|
|6.||Cai, Ren-Zhi: 2 articles (01/2014 - 01/2014)|
|7.||Szalontay, Luca: 2 articles (01/2014 - 02/2012)|
|8.||Perez, Roberto: 2 articles (01/2014 - 09/2012)|
|9.||Rincon, Ricardo: 2 articles (01/2014 - 09/2012)|
|10.||Klukovits, Anna: 2 articles (01/2014 - 02/2012)|
09/01/2012 - "Treatment with MIA-602 significantly reduced tumor growth. "
10/01/2011 - "The effect of MIA-602 was mediated nearly as well in tumors that expressed only the SV1 receptor compared to those in which both SV1 and pGHRH-R were present, although a difference could be detected at the level of cell signaling."
01/21/2014 - "In vivo, MIA-602 was more effective than MIA-606 and MIA-690 and decreased 22Rv1 xenograft tumor volumes in mice by 63% after 3 wk (P < 0.05). "
01/01/2014 - "Therapy with MIA-602 significantly reduced tumor growth and enhanced the efficacy of doxorubicin in both cell lines. "
06/01/2015 - "We also treated seven normal and PTC tumor thyroid cells in vitro with a GHRH antagonist, MIA-602, to compare its anti-proliferation and anti-invasion potential against vehicle-treated cells. "
|2.||Glioblastoma (Glioblastoma Multiforme)
11/15/2010 - "Our study demonstrates that GHRH antagonists induce apoptosis through key proapoptotic pathways and shows the efficacy of MIA-602 for experimental treatment of glioblastoma."
11/15/2010 - "The effects of new growth hormone-releasing hormone (GHRH) antagonists JMR-132 and MIA-602 and their mechanism of action were investigated on 2 human glioblastoma cell lines, DBTRG-05 and U-87MG, in vitro and in vivo. "
11/15/2010 - "After treatment with MIA-602 and JMR-132, the reduction rate in the growth of DBTRG-05 glioblastoma, xenografted into nude mice, was significant and tumor doubling time was also significantly extended when compared with controls. "
|3.||Breast Neoplasms (Breast Cancer)
10/01/2011 - "In conclusion, our study shows that MIA-602 is effective against a wide range of breast cancer cells in vitro, independently of their receptor positivity, suggesting the potential use of GHRH antagonists also in the treatment of triple-negative breast cancer. "
10/01/2011 - "We investigated the effects of a novel GHRH antagonist, MIA-602, on nine breast cancer cell lines, differing in their expression for estrogen-, progesterone- and HER-2 receptors. "
|5.||Prostatic Neoplasms (Prostate Cancer)
|2.||Factor IX (PTC)
|3.||Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)
|4.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|5.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|6.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|8.||Gonadotropin-Releasing Hormone (GnRH)
|10.||PhAcTyr(1)- Arg(2)- P(H)e(4- CL)(6)- Ala(8)- Tyr(Me)(10)- His(11)- Abu(15)- His(20)- Nle(27)- Arg(28)- HLCr(29)- GHRH(1-29)NH2
|1.||Heterologous Transplantation (Xenotransplantation)